<DOC>
	<DOC>NCT00300430</DOC>
	<brief_summary>The primary purpose of this study is to test the safety and the effects of using an investigational drug regimen; once daily ABT-335 (Investigational drug) administered in combination with once daily atorvastatin calcium, rosuvastatin calcium or simvastatin in patients with abnormal lipid levels in the blood.</brief_summary>
	<brief_title>Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Calcium, Dietary</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Adult male and female subjects who voluntarily sign the informed consent. Subject has successfully completed one of the three ABT335, rosuvastatin, simvastatin and atorvastatin combination therapy studies. Subject is using or will use investigational medications, except as approved by Abbott. Subject has prematurely discontinued his/her initial therapy one of the prior ABT335, rosuvastatin, simvastatin and atorvastatin calcium combination therapy studies.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>